OBJECTIVE: To determine long-term tumor recurrence rates after treatment of primary nonmelanoma skin cancer (NMSC). Data are currently insufficient to permit evidence-based choices among treatments for NMSC. DESIGN: Prospective study of an inception cohort observed for a median of 6.6 years after treatment. SETTING: Dermatology clinic at a Veterans Affairs hospital. Care was provided by dermatology resident or attending physicians. PATIENTS: Consecutive sample of all 495 patients with 616 primary NMSCs diagnosed in 1999 and 2000 and treated with electrodessication and curettage (ED&C), excision, or Mohs surgery. Follow-up was available for 608 tumors (99%). MAIN OUTCOME MEASURE: Tumor recurrence, determined by medical record review, with validation by clinical examination. RESULTS: The mean age at diagnosis was 71 years; 97% were men. Overall, 127 tumors were treated with ED&C (20.9%); 309 with excision (50.8%); and 172 with Mohs surgery (28.3%). Over the course of the study, 21 tumors recurred (3.5% [95% confidence interval (CI), 2.2%-5.2%]): 2 after ED&C (1.6% [95% CI, 0.2%-5.6%]), 13 after excision (4.2% [95% CI, 2.2%-7.1%]), and 6 after Mohs surgery (3.5% [95% CI, 1.3%-7.4%]). CONCLUSIONS: Recurrence of primary NMSC after treatment occurred in less than 5% of tumors. The recurrence rate after ED&C was lower than expected, and the recurrence rate after Mohs surgery was higher than expected. These findings may be related to the risk for recurrence in the treatment groups.
OBJECTIVE: To determine long-term tumor recurrence rates after treatment of primary nonmelanoma skin cancer (NMSC). Data are currently insufficient to permit evidence-based choices among treatments for NMSC. DESIGN: Prospective study of an inception cohort observed for a median of 6.6 years after treatment. SETTING: Dermatology clinic at a Veterans Affairs hospital. Care was provided by dermatology resident or attending physicians. PATIENTS: Consecutive sample of all 495 patients with 616 primary NMSCs diagnosed in 1999 and 2000 and treated with electrodessication and curettage (ED&C), excision, or Mohs surgery. Follow-up was available for 608 tumors (99%). MAIN OUTCOME MEASURE: Tumor recurrence, determined by medical record review, with validation by clinical examination. RESULTS: The mean age at diagnosis was 71 years; 97% were men. Overall, 127 tumors were treated with ED&C (20.9%); 309 with excision (50.8%); and 172 with Mohs surgery (28.3%). Over the course of the study, 21 tumors recurred (3.5% [95% confidence interval (CI), 2.2%-5.2%]): 2 after ED&C (1.6% [95% CI, 0.2%-5.6%]), 13 after excision (4.2% [95% CI, 2.2%-7.1%]), and 6 after Mohs surgery (3.5% [95% CI, 1.3%-7.4%]). CONCLUSIONS: Recurrence of primary NMSC after treatment occurred in less than 5% of tumors. The recurrence rate after ED&C was lower than expected, and the recurrence rate after Mohs surgery was higher than expected. These findings may be related to the risk for recurrence in the treatment groups.
Authors: N W J Smeets; D I M Kuijpers; P Nelemans; J U Ostertag; M E J M Verhaegh; G A M Krekels; H A M Neumann Journal: Br J Dermatol Date: 2004-07 Impact factor: 9.302
Authors: Mary-Margaret Chren; Anju P Sahay; Laura P Sands; Leah Maddock; Karla Lindquist; Daniel Bertenthal; Peter Bacchetti Journal: Med Care Date: 2004-10 Impact factor: 2.983
Authors: Christopher Metchnikoff; Thaddeus Mully; Jonathan P Singer; Jeffrey A Golden; Sarah T Arron Journal: J Am Acad Dermatol Date: 2012-01-29 Impact factor: 11.527
Authors: Amelia K Hausauer; Toby Maurer; Kieron S Leslie; Rupa Parvataneni; Sarah E Stuart; Mary-Margaret Chren Journal: JAMA Dermatol Date: 2013-02 Impact factor: 10.282
Authors: Eleni Linos; Rupa Parvataneni; Sarah E Stuart; W John Boscardin; C Seth Landefeld; Mary-Margaret Chren Journal: JAMA Intern Med Date: 2013-06-10 Impact factor: 21.873
Authors: M R Wehner; N Dalma; C Landefeld; A Pare-Anastasiadou; I Koutelidas; M M Chren; N Aji; C E Teng; B A Koenig; J Tang; K Covinsky; E Linos Journal: Br J Dermatol Date: 2018-07-12 Impact factor: 9.302
Authors: Mary-Margaret Chren; Eleni Linos; Jeanette S Torres; Sarah E Stuart; Rupa Parvataneni; W John Boscardin Journal: J Invest Dermatol Date: 2012-11-29 Impact factor: 8.551
Authors: Alejandro Tormo; Francisco Celada; Silvia Rodriguez; Rafael Botella; Antonio Ballesta; Michael Kasper; Zoubir Ouhib; Manuel Santos; Jose Perez-Calatayud Journal: J Contemp Brachytherapy Date: 2014-06-03